Get the Stockscreener App
15.73
1.93%
-0.31
After Hours:
16.04
0.31
+1.97%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $15.73, with a volume of 8.56M.
It is down -1.93% in the last 24 hours and down -4.55% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$16.04
Open:
$16.04
24h Volume:
8.56M
Relative Volume:
0.81
Market Cap:
$18.32B
Revenue:
$14.57B
Net Income/Loss:
$-296.50M
P/E Ratio:
-60.73
EPS:
-0.259
Net Cash Flow:
$1.64B
1W Performance:
-0.25%
1M Performance:
-4.55%
6M Performance:
+34.44%
1Y Performance:
+79.57%
1-Day Range:
$15.64
$16.22
1-Week Range:
$15.64
$16.63
52-Week Range:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
15.73 | 19.01B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris launches €650M 4.250% senior notes due 2033 offering - TradingView
Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033 - Stock Titan
Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS) - simplywall.st
Viatris Inc. (VTRS) Stock Analysis: Navigating Growth Prospects with an 8.09% Potential Upside - DirectorsTalk Interviews
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story - Yahoo Finance
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
[424B5] Viatris Inc Prospectus Supplement (Debt Securities) - Stock Titan
A Look at Viatris Inc (VTRS) After 3.4% Gain -- GF Value $11.01 vs Price $16.31 - GuruFocus
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.70% Potential Upside with a Strong Dividend Yield - DirectorsTalk Interviews
Viatris (VTRS) Holds Steady Near Support Amid Flat Trading SessionRSI Overbought Alerts - newsline.com
Liquidity Mapping Around (VTRS) Price Events - Stock Traders Daily
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Investors brace for Viatris earnings as CFO departure looms By Investing.com - Investing.com Nigeria
Here's Why Viatris (VTRS) is a Strong Value Stock - Yahoo Finance
Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - marketscreener.com
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring An 11% Potential Upside Amid Mixed Metrics - DirectorsTalk Interviews
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy? - simplywall.st
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Top Brass Sued by Investor Over India Facility Problems - Bloomberg Law News
Argus Raises Viatris Price Target to $18 From $15 - Moomoo
Why (VTRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Analyst Report Highlights Viatris Inc’s Strategic Positioning Amid Generic Drug CompetitionLow Estimate Range - newsline.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS) Under Pressure: Support Levels Tested After 1.5% DeclineVolatility Smile - newsline.com
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
Viatris Inc. (VTRS) Stock Analysis: Investor Outlook on a Healthcare Giant with an 8.44% Upside Potential - DirectorsTalk Interviews
Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam - Yahoo Finance
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders - simplywall.st
Viatris Inc.: - marketscreener.com
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Viatris (VTRS) price target increased by 10.47% to 17.48 - MSN
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
VTRS Maintains Overweight Rating -- Price Target Raised to $22 - GuruFocus
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - Yahoo! Finance Canada
Viatris CFO leaving Canonsburg pharma giant - MSN
Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating - Moomoo
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - Sahm
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Me - GuruFocus
TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viatris Inc Stock (VTRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Campbell Paul | See Remarks |
Mar 23 '26 |
Sale |
13.28 |
21,350 |
283,539 |
366,288 |
1.65%
3.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):